Investor relations
Financial calendar
Zinzino Interim report Q3 2025
Zinzino Delårsrapport Q3 2025
Year-End Report 2025
Bokslutskommuniké 2025
Zinzino Interim report Q1 2026
Zinzino Delårsrapport Q1 2026
Financial reports
Press releases
ZINZINO AB (PUBL.): ZINZINO ACQUIRES TRUVY TO INCREASE DISTRIBUTION CAPACITY IN NORTH AMERICA, LATIN AMERICA, AND SOUTH KOREA
25. september 2025, 09:00
OpnaZINZINO AB (PUBL.): ZINZINO ACQUIRES BODĒ PRO TO INCREASE DISTRIBUTION POWER IN NORTH AMERICA AND JAPAN
12. september 2025, 16:30
OpnaZINZINO AB (PUBL.): LETTER OF INTENT TO ACQUIRE TRUVY FOR INCREASED DISTRIBUTION POWER IN NORTH AMERICA, LATIN AMERICA, AND SOUTH KOREA
05. september 2025, 14:00
OpnaZINZINO AB (PUBL.): New study unveils global snapshot on Omega-3 deficiency – and why high-precision testing plus an enhanced formula can close the gap
18. ágúst 2025, 15:51
OpnaZINZINO AB (PUBL.): ZINZINO INITIATES NEGOTIATIONS FOR PART OWNERSHIP IN ANDORRA-BASED XION INTERNATIONAL GROUP FOR FURTHER DEVELOPMENT OF PROPRIETARY OMEGA-3 OIL AND SPIRULINA
14. júlí 2025, 14:00
OpnaZINZINO AB (PUBL.): Zinzino announces Philippines as next step in its global expansion
12. júní 2025, 13:30
OpnaZINZINO AB (PUBL.): Zinzino acquires assets from Ecosystem for increased distribution power in France and DOM-TOM
10. júní 2025, 13:30
OpnaZINZINO AB (PUBL.): Zinzino announces China as the next step in its global expansion
16. maí 2025, 08:00
OpnaZINZINO AB (PUBL.): NOTICE TO THE ANNUAL GENERAL MEETING OF ZINZINO AB ON 28 MAY 2025
28. apríl 2025, 17:00
OpnaZINZINO AB (PUBL.): Zinzino acquires Valentus Global to increase distribution power in Europe
11. apríl 2025, 16:00
OpnaZINZINO AB (PUBL.): Zinzino announces New Zealand as next step in its global expansion
11. mars 2025, 13:26
OpnaZINZINO AB (PUBL.): ANNOUNCES ACQUISITION OF ZURVITA’S ASSETS FOLLOWING SUCCESSFUL CHAPTER 11 PROCESS
14. febrúar 2025, 08:00
OpnaZINZINO AB (PUBL.): ENTERS INTO AGREEMENT TO PROVIDE DIP FINANCING TO ZURVITA INITIATING CHAPTER 11 PROCESS
21. desember 2024, 20:00
OpnaZINZINO AB (PUBL): Zinzino announces Canary Islands as next step in its global expansion
13. nóvember 2024, 15:00
OpnaZINZINO AB (PUBL.): ZINZINO ACQUIRES 49% OF CYPRIOT OLIVE OIL PRODUCER CLEANTHI ALPHA-OLENIC LTD
27. júní 2024, 11:00
OpnaZINZINO AB (PUBL): LETTER OF INTENT TO ACQUIRE ZURVITA INCREASES DISTRIBUTION POWER IN NORTH AMERICA
17. júní 2024, 11:00
OpnaZINZINO AB (PUBL): Zinzino announces Serbia as next step in its global expansion
11. júní 2024, 15:30
OpnaZINZINO AB (PUBL): Zinzino now seeks acquisitions in the US and Asia to increase distribution power
07. júní 2024, 12:00
OpnaZINZINO AB (PUBL): Zinzino acquires assets in Xelliss – strategic reinforcement in southern Europe and in the microalgae spirulina
12. maí 2024, 13:00
OpnaZINZINO AB (PUBL): NOTICE OF ANNUAL GENERAL MEETING IN ZINZINO AB ON MAY 27, 2024
26. apríl 2024, 08:00
OpnaZINZINO AB (PUBL): Zinzino and ACN, enter a strategic partnership in Europe, and in connection with it Zinzino carries out a directed new issue of B shares for SEK 10.4 million.
29. janúar 2024, 10:00
OpnaZINZINO AB (PUBL): Zinzino changes Certified Adviser to Carnegie Investment Bank AB (publ)
30. nóvember 2023, 09:00
OpnaZINZINO AB (PUBL): Zinzino announces Mexico as next step in its global expansion
22. september 2023, 08:00
OpnaZINZINO AB (PUBL.): NOTICE TO THE ANNUAL MEETING OF ZINZINO AB ON MAY 31, 2023
02. maí 2023, 08:00
OpnaZINZINO AB (PUBL): Zinzino launches Turkey as a next market on their road towards global expansion
07. mars 2023, 14:30
OpnaGrowing interest in personal health and customized supplements can be a great investment case
28. nóvember 2022, 14:30
OpnaZinzino announces the launch of Singapore as next step in their global expansion
07. apríl 2022, 11:30
OpnaZINZINO AB (PUBL): Zinzino acquires brand portfolio with Swiss skincare and supplements
06. apríl 2022, 09:30
OpnaZINZINO AB (PUBL): MEMBERS OF THE NOMINATION COMMITTEE FOR ZINZINO AB'S ANNUAL GENERAL MEETING IN 2022
18. nóvember 2021, 14:00
OpnaZINZINO AB (PUBL): Zinzino announces the launch of South Africa as next step in their global expansion
09. nóvember 2021, 11:30
OpnaZINZINO AB (PUBL): Zinzino announces launch of Taiwan as next step in the global expansion
09. september 2021, 13:00
OpnaZINZINO AB (PUBL): Zinzino announces the launch of Malaysia as next step in their global expansion
03. júní 2021, 11:00
OpnaZINZINO AB (PUBL): A new signature BalanceOil from the pioneers of test-based nutrition
15. apríl 2021, 15:00
OpnaZINZINO AB (PUBL): Zinzino announces the launch of India as next step in their global expansion strategy
06. apríl 2021, 14:00
OpnaZINZINO AB (PUBL): ZINZINO MOVES TO THE PREMIER SEGMENT OF FIRST NORTH GROWTH MARKET
16. september 2020, 10:00
OpnaZINZINO AB (PUBL): ONE-TIME EFFECT DUE TO CHANGED ACCOUNTING FOR DISTRIBUTOR REMUNERATION IMPROVES Q1 2020 WITH SEK 22.2 MILLION BEFORE TAX
05. maí 2020, 12:00
OpnaZINZINO AB (PUBL): Zinzino and Life Leadership collaborate to provide test-based nutrition to expanding markets
25. október 2019, 16:40
OpnaZINZINO AB (PUBL.) APPOINTED “GROWTH COMPANY OF THE YEAR 2017” BY DIRECT SELLING SWEDEN
01. júní 2018, 11:00
OpnaZINZINO AB (PUBL): Q1; CONTINUED SOUND GROWTH AND STRONG PROFITABILITY IMPROVEMENT, EBITDA RISING BY 45%
15. maí 2018, 08:00
OpnaZINZINO AB (PUBL): STRONG GROWTH AND PROPOSAL FOR GREATLY INCREASED DIVIDENDS
28. febrúar 2018, 08:00
OpnaZINZINO AB (PUBL): PRELIMINARY SALES REPORT FOR Q4 AND 2017 WITH PROPOSAL TO INCREASE DIVIDEND
19. janúar 2018, 18:00
OpnaInterim report, July – September 2017: IMPROVED GROSS MARGINS AND STRONG GROWTH IN THE DOMESTIC MARKET.
13. nóvember 2017, 08:30
OpnaZinzino launches groundbreaking product: BalanceOil Vegan for the heart and brain
20. október 2017, 13:00
OpnaZINZINO AB (PUBL): CORRECTION: PRELIMINARY SALES REPORT THIRD QUARTER 2017
10. október 2017, 17:00
OpnaInterim Report, Zinzino, April – June 2017: Very strong growth of 28% and full-scale launch of a new digital platform
31. ágúst 2017, 09:00
OpnaZINZINO LAUNCHES VIVA, A NEW DIETARY SUPPLEMENT PROMOTING BETTER SLEEP, REDUCING STRESS AND INCREASING WELL-BEING
30. júní 2017, 15:00
OpnaZinzino AB (publ.) appointed “Growth Company of the Year 2016” in direct sales
02. júní 2017, 16:00
OpnaZinzino begins selling in Switzerland ”Rich in capital and an important market”
16. maí 2017, 16:00
OpnaInterim Report, January – March 2017: Zinzino continues to deliver strong growth and is well prepared for increased profitability
10. maí 2017, 09:00
OpnaZinzino taking the Omega-6/Omega-3 concept to new heights with water-miscible AquaX oil
07. júlí 2016, 16:24
OpnaSweden's Zinzino is improving its foothold in Europe – with the establishment of operations in Germany
22. febrúar 2016, 08:00
OpnaZinzino launches Zinzino LeanShake – a nutritious meal replacement for weight control
11. desember 2015, 11:58
OpnaSwedish Zinzino continues to grow internationally with its establishment in Canada
17. september 2015, 09:28
OpnaZinzino AB (publ) acquires further 13.8 per cent of Faun Pharma AS – safeguarding continued research and expanded product range
06. mars 2015, 10:29
OpnaThe stock
Zinzino Interim Report Q2 2025 – Interview
Carlsquare interviews CEO Dag Bergheim Pettersen about Zinzino’s Interim Report for Q2 2025.
Sustainability Report
Read more about our sustainability approach, targets and 2023 performance.
Elizabeta Sekulovska
shares@zinzino.com
+46 (0)763 066 954
Fredrik Nielsen
shares@zinzino.com
+46 (0)707 900 174
Certified Adviser
All companies whose shares are to be traded on the Nasdaq First North Premier Growth Market have a certified adviser who guides and supports the company through the listing process. Subsequently, the adviser monitors that the company complies with First North's regulations for providing information to the market and investors. DNB Carnegie Investment Bank AB (publ) is the Certified Adviser for Zinzino AB.
Certified Adviser:
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB (publ)
Phone: +46 (0)738 564 265
E-mail: certifiedadviser@carnegie.se
Why invest in Zinzino
Strong market position and distribution
Zinzino has strong sales organisations in its principal markets with good relationships with its customer base. The broad product portfolio attracts new customer groups and thereby generates growth. Through an updated IT platform and logistics system, Zinzino is well equipped for the expected sales growth in the coming years.
Attractive cash flow enables increased stock dividends and gives a good direct return
Zinzino’s business has a very strong cash-generating capability. Effective management of working capital combined with investments that quickly generate revenue and marginal improvements generate a strong cash flow. Thus, dividends can be distributed in accordance with the target of at least 50 per cent of the free cash flow.
A clear global strategy with a growth-driven, future-proof business model
Zinzino is one of Europe’s fastest-growing direct sales companies with an aggressive global expansion strategy. The Scandinavian-based health tech company is currently operating in Europe, North America, Asia, Australia, India and Africa. The overall company strategy and business model is to achieve profitable growth in new as well as existing markets. The massive growth momentum of the past decade is expected to stay constant thanks to the stability and structure of the business model in combination with top-of-the-line digital market tools as well as continuous company acquisitions.
Help improve the health of the world
Our product concept is to give health back to the world. Our goal is to get the best out of people with enthusiasm, encouragement and a great deal of energy. We are the most customer-focused direct sales company in the world. Our most important product concept, Balance, is showing continued good growth and we currently have over 500,000 test results based on blood tests in our database. We are the company that has done the most fatty acid analyses in the world.
Product development at the leading edge
Through efficient product development in-house, the company has developed a number of new products in health in which it owns its own important intellectual property rights. The newly developed products are manufactured in our own efficient production facility which means that we have 100% quality control. Zinzino’s strategy in the coming years includes continued product development at the leading edge.
Attractive cash flow enables increased stock dividends and gives a good direct return
Zinzino’s business has a very strong cash-generating capability. Effective management of working capital combined with investments that quickly generate revenue and marginal improvements generate a strong cash flow. Thus, dividends can be distributed in accordance with the target of at least 50 per cent of the free cash flow.
A clear global strategy with a growth-driven, future-proof business model
Zinzino is one of Europe’s fastest-growing direct sales companies with an aggressive global expansion strategy. The Scandinavian-based health tech company is currently operating in Europe, North America, Asia, Australia, India and Africa. The overall company strategy and business model is to achieve profitable growth in new as well as existing markets. The massive growth momentum of the past decade is expected to stay constant thanks to the stability and structure of the business model in combination with top-of-the-line digital market tools as well as continuous company acquisitions.
Help improve the health of the world
Our product concept is to give health back to the world. Our goal is to get the best out of people with enthusiasm, encouragement and a great deal of energy. We are the most customer-focused direct sales company in the world. Our most important product concept, Balance, is showing continued good growth and we currently have over 500,000 test results based on blood tests in our database. We are the company that has done the most fatty acid analyses in the world.
Product development at the leading edge
Through efficient product development in-house, the company has developed a number of new products in health in which it owns its own important intellectual property rights. The newly developed products are manufactured in our own efficient production facility which means that we have 100% quality control. Zinzino’s strategy in the coming years includes continued product development at the leading edge.
Strong market position and distribution
Zinzino has strong sales organisations in its principal markets with good relationships with its customer base. The broad product portfolio attracts new customer groups and thereby generates growth. Through an updated IT platform and logistics system, Zinzino is well equipped for the expected sales growth in the coming years.
A clear global strategy with a growth-driven, future-proof business model
Zinzino is one of Europe’s fastest-growing direct sales companies with an aggressive global expansion strategy. The Scandinavian-based health tech company is currently operating in Europe, North America, Asia, Australia, India and Africa. The overall company strategy and business model is to achieve profitable growth in new as well as existing markets. The massive growth momentum of the past decade is expected to stay constant thanks to the stability and structure of the business model in combination with top-of-the-line digital market tools as well as continuous company acquisitions.
Help improve the health of the world
Our product concept is to give health back to the world. Our goal is to get the best out of people with enthusiasm, encouragement and a great deal of energy. We are the most customer-focused direct sales company in the world. Our most important product concept, Balance, is showing continued good growth and we currently have over 500,000 test results based on blood tests in our database. We are the company that has done the most fatty acid analyses in the world.
Product development at the leading edge
Through efficient product development in-house, the company has developed a number of new products in health in which it owns its own important intellectual property rights. The newly developed products are manufactured in our own efficient production facility which means that we have 100% quality control. Zinzino’s strategy in the coming years includes continued product development at the leading edge.
Strong market position and distribution
Zinzino has strong sales organisations in its principal markets with good relationships with its customer base. The broad product portfolio attracts new customer groups and thereby generates growth. Through an updated IT platform and logistics system, Zinzino is well equipped for the expected sales growth in the coming years.
Attractive cash flow enables increased stock dividends and gives a good direct return
Zinzino’s business has a very strong cash-generating capability. Effective management of working capital combined with investments that quickly generate revenue and marginal improvements generate a strong cash flow. Thus, dividends can be distributed in accordance with the target of at least 50 per cent of the free cash flow.
Help improve the health of the world
Our product concept is to give health back to the world. Our goal is to get the best out of people with enthusiasm, encouragement and a great deal of energy. We are the most customer-focused direct sales company in the world. Our most important product concept, Balance, is showing continued good growth and we currently have over 500,000 test results based on blood tests in our database. We are the company that has done the most fatty acid analyses in the world.
Product development at the leading edge
Through efficient product development in-house, the company has developed a number of new products in health in which it owns its own important intellectual property rights. The newly developed products are manufactured in our own efficient production facility which means that we have 100% quality control. Zinzino’s strategy in the coming years includes continued product development at the leading edge.
Strong market position and distribution
Zinzino has strong sales organisations in its principal markets with good relationships with its customer base. The broad product portfolio attracts new customer groups and thereby generates growth. Through an updated IT platform and logistics system, Zinzino is well equipped for the expected sales growth in the coming years.
Attractive cash flow enables increased stock dividends and gives a good direct return
Zinzino’s business has a very strong cash-generating capability. Effective management of working capital combined with investments that quickly generate revenue and marginal improvements generate a strong cash flow. Thus, dividends can be distributed in accordance with the target of at least 50 per cent of the free cash flow.
A clear global strategy with a growth-driven, future-proof business model
Zinzino is one of Europe’s fastest-growing direct sales companies with an aggressive global expansion strategy. The Scandinavian-based health tech company is currently operating in Europe, North America, Asia, Australia, India and Africa. The overall company strategy and business model is to achieve profitable growth in new as well as existing markets. The massive growth momentum of the past decade is expected to stay constant thanks to the stability and structure of the business model in combination with top-of-the-line digital market tools as well as continuous company acquisitions.
Product development at the leading edge
Through efficient product development in-house, the company has developed a number of new products in health in which it owns its own important intellectual property rights. The newly developed products are manufactured in our own efficient production facility which means that we have 100% quality control. Zinzino’s strategy in the coming years includes continued product development at the leading edge.
Strong market position and distribution
Zinzino has strong sales organisations in its principal markets with good relationships with its customer base. The broad product portfolio attracts new customer groups and thereby generates growth. Through an updated IT platform and logistics system, Zinzino is well equipped for the expected sales growth in the coming years.
Attractive cash flow enables increased stock dividends and gives a good direct return
Zinzino’s business has a very strong cash-generating capability. Effective management of working capital combined with investments that quickly generate revenue and marginal improvements generate a strong cash flow. Thus, dividends can be distributed in accordance with the target of at least 50 per cent of the free cash flow.
A clear global strategy with a growth-driven, future-proof business model
Zinzino is one of Europe’s fastest-growing direct sales companies with an aggressive global expansion strategy. The Scandinavian-based health tech company is currently operating in Europe, North America, Asia, Australia, India and Africa. The overall company strategy and business model is to achieve profitable growth in new as well as existing markets. The massive growth momentum of the past decade is expected to stay constant thanks to the stability and structure of the business model in combination with top-of-the-line digital market tools as well as continuous company acquisitions.
Help improve the health of the world
Our product concept is to give health back to the world. Our goal is to get the best out of people with enthusiasm, encouragement and a great deal of energy. We are the most customer-focused direct sales company in the world. Our most important product concept, Balance, is showing continued good growth and we currently have over 500,000 test results based on blood tests in our database. We are the company that has done the most fatty acid analyses in the world.